Abstract
Objective: To investigate if adjunctive valacyclovir, an antiviral medication, reduces symptoms of persistent schizophrenia in individuals who are seropositive for cytomegalovirus (CMV). Method: N = 47 CMV seropositive schizophrenia outpatients were randomly assigned to receive valacyclovir 1 g twice daily (n = 24) or placebo (n = 23) for 16 weeks after a 2-week placebo run-in. Symptoms were assessed biweekly. Results: There was no significant difference in the change of positive, negative, general, or total PANSS symptoms between the valacyclovir vs. the placebo group. Conclusions: The study did not demonstrate benefit of adjunctive valacyclovir for schizophrenia individuals with persistent symptoms who are CMV seropositive.
Original language | English (US) |
---|---|
Pages (from-to) | 147-149 |
Number of pages | 3 |
Journal | Schizophrenia Research |
Volume | 107 |
Issue number | 2-3 |
DOIs | |
State | Published - Feb 2009 |
Keywords
- Antiviral medication
- Cytomegalovirus
- Herpes virus
- Schizophrenia
- Valtrex
ASJC Scopus subject areas
- Psychiatry and Mental health
- Biological Psychiatry